ID   SP-53
AC   CVCL_C122
SY   SP53; DBsp53; DB-sp53
DR   cancercelllines; CVCL_C122
DR   Cosmic; 1070710
DR   Cosmic; 2296998
DR   GEO; GSM119539
DR   Progenetix; CVCL_C122
DR   Wikidata; Q54955389
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2548699;
RX   PubMed=8971032;
RX   PubMed=9738977;
RX   PubMed=11061568;
RX   PubMed=12683869;
RX   PubMed=16960149;
RX   PubMed=26194763;
RX   PubMed=29666304;
CC   Population: Japanese.
CC   Doubling time: 57 hours (PubMed=11061568).
CC   HLA typing: A*02,24; B*40,56; C*03,04 (Direct_author_submission).
CC   Omics: Array-based CGH.
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_D022 ! SP-49
OI   CVCL_C121 ! SP-50B
OI   CVCL_M655 ! SP-52EB
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-09-24; Version: 20
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=2548699; DOI=10.1002/1097-0142(19890915)64:6<1248::AID-CNCR2820640614>3.0.CO;2-5;
RA   Daibata M., Kubonishi I., Eguchi T., Yano S., Ohtsuki Y., Miyoshi I.;
RT   "The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B)
RT   and Epstein-Barr virus nuclear antigen-negative (SP-53) cell lines with
RT   t(11;14)(q13;q32) chromosome abnormality from an intermediate
RT   lymphocytic lymphoma.";
RL   Cancer 64:1248-1253(1989).
//
RX   PubMed=8971032; DOI=10.1128/JVI.70.12.9003-9007.1996; PMCID=PMC191000;
RA   Daibata M., Kubonishi I., Miyoshi I.;
RT   "Differential tumorigenicity between Epstein-Barr virus genome-positive
RT   and genome-negative cell lines with t(11;14)(q13;q32) derived from
RT   mantle cell lymphoma.";
RL   J. Virol. 70:9003-9007(1996).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=11061568; DOI=10.18926/AMO/32293;
RA   Jin Z., Teramoto N., Yoshino T., Takada K., Oka T., Hayashi K.,
RA   Akagi T.;
RT   "Characterization of Epstein-Barr virus-infected mantle cell lymphoma
RT   lines.";
RL   Acta Med. Okayama 54:193-200(2000).
//
RX   PubMed=12683869; DOI=10.5858/2003-127-0424-COMCLC;
RA   Amin H.M., McDonnell T.J., Medeiros L.J., Rassidakis G.Z.,
RA   Leventaki V., O'Connor S.L., Keating M.J., Lai R.;
RT   "Characterization of 4 mantle cell lymphoma cell lines. Establishment
RT   of an in vitro study model.";
RL   Arch. Pathol. Lab. Med. 127:424-431(2003).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=26194763; DOI=10.1182/blood-2015-01-624585; PMCID=PMC4582332;
RA   Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y.,
RA   Isik E., Letai A.G., Lossos I.S.;
RT   "Direct and immune-mediated cytotoxicity of interleukin-21 contributes
RT   to antitumor effects in mantle cell lymphoma.";
RL   Blood 126:1555-1564(2015).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//